🇺🇸 FDA
Pipeline program

100 mg Resmetirom Tablet

MGL-3196-21

Phase 1 small_molecule completed

Quick answer

100 mg Resmetirom Tablet for Renal Impairment is a Phase 1 program (small_molecule) at MADRIGAL PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
MADRIGAL PHARMACEUTICALS, INC.
Indication
Renal Impairment
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials